On March 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel (Yescarta^®) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Chapters are the heart of ONS at your local level, and during its January 19, 2021, meeting, the ONS Board of Directors discussed chapter-specific feedback from the leadership survey. Chapters have relied on virtual connection recently because of the pandemic, and they are still adapting to ONS’s new chapter standards. The Board identified opportunities to connect and communicate with chapters to support them in those goals. Highlights from that discussion and other actions taken during the January meeting follow, and ONS members can view the full minutes at ons.org/board-minutes.

Since taking office, President Joe Biden has made good on his campaign promises to change federal tone and action in response to Americans’ concerns about health care and racial equity. On January 28, 2021, Biden signed an executive order (EO) extending the timeline for more Americans to apply for and receive access to the Affordable Care Act, reiterating his commitment to the law known as Obamacare. Biden also signed an EO supporting women’s health by reinstating Title X protections. 

Oncology nurses hold a unique position in improving symptom management and health outcomes in people with cancer, and their contributions to the body of symptom science are critical. In support of that work, ONS embarked on a landmark partnership with the National Institute of Nursing Research and National Cancer Institute's Center for Cancer Research to present the inaugural Colloquium on Symptom Science Advances in Oncology Nursing on February 4–5, 2021.

How does a new graduate nurse develop connections and community in the nursing world? We asked ourselves that exact question before graduating from Boise State University’s School of Nursing, where we served as copresidents of the school’s student nurses’ association. We wanted to bridge the gap between students and professional nurses, and the answer came soon after, when our local ONS chapter invited us to join and serve as student liaisons to its board of directors.

Nearly 1.9 million people in the United States will be diagnosed with cancer in 2021. However, overall cancer screenings dropped roughly 80% in 2020 because of the COVID-19 coronavirus pandemic and statewide stay-at-home orders. To combat the decline, the Centers for Disease Control and Prevention’s (CDC’s) new outreach campaign reminds patients and providers of the importance of cancer screening. 

On March 3, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena®) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib.

As the third most common cancer among both men and women, colorectal cancer is a reality for the more than 1 million people in the United States who are living with or have a history of the disease. Advancements in early detection and treatment have improved outcomes, but many survivors experience late and long-term side effects that may vary in duration, intensity, and impact on their quality of life. Clinicians must tailor each survivorship care plan for a patient’s cancer type, stage, treatment received, psychosocial implications, and side effects or toxicities.

Cancer-related mortality fell by 2.4% from 2017–2018, the largest-ever one-year drop in cancer deaths and a continuation of the downward trend the United States has seen since 1991, the American Cancer Society (ACS) reported in Cancer Facts and Figures, 2021.

Patient education is an essential aspect of cancer prevention. Nearly 1.9 million people in the United States will be diagnosed with cancer in 2021, and modifiable risk factors are responsible for approximately 35% of cancer-related deaths. However, less than half of Americans understand the major risk factors that contribute to the development of cancer.